These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1128 related articles for article (PubMed ID: 3704665)
1. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665 [TBL] [Abstract][Full Text] [Related]
2. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. Berk PD; Goldberg JD; Silverstein MN; Weinfeld A; Donovan PB; Ellis JT; Landaw SA; Laszlo J; Najean Y; Pisciotta AV; Wasserman LR N Engl J Med; 1981 Feb; 304(8):441-7. PubMed ID: 7005681 [TBL] [Abstract][Full Text] [Related]
3. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Nand S; Stock W; Godwin J; Fisher SG Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610 [TBL] [Abstract][Full Text] [Related]
4. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Ellis JT; Peterson P; Geller SA; Rappaport H Semin Hematol; 1986 Apr; 23(2):144-55. PubMed ID: 3704666 [TBL] [Abstract][Full Text] [Related]
5. [Efficacious treatment of a fatal blood disease: polycythemia vera]. Sánchez Fayos J; Román Barbero A; Nevado Reviriego I Sangre (Barc); 1997 Jun; 42(3):215-8. PubMed ID: 9381264 [No Abstract] [Full Text] [Related]
7. Neurologic complications of polycythemia and their impact on therapy. Newton LK Oncology (Williston Park); 1990 Mar; 4(3):59-64; discussion 64-6. PubMed ID: 2144446 [TBL] [Abstract][Full Text] [Related]
8. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T; Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279 [TBL] [Abstract][Full Text] [Related]
9. Polycythemia vera: a retrospective and reprise. Berlin NI; Wasserman LR J Lab Clin Med; 1997 Oct; 130(4):365-73. PubMed ID: 9358074 [TBL] [Abstract][Full Text] [Related]
10. The choice of treatment in polycythaemia vera. Najean Y; Dresch C Drugs Exp Clin Res; 1986; 12(1-3):177-80. PubMed ID: 3525073 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD). Murphy S Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227 [TBL] [Abstract][Full Text] [Related]
12. Treatment of the myeloproliferative disorders with 32P. Berlin NI Eur J Haematol; 2000 Jul; 65(1):1-7. PubMed ID: 10914933 [TBL] [Abstract][Full Text] [Related]
16. [Treatment of polycythemia. I--Using radiophosphorus with or without treatment in 483 patients over 65 years of age]. Najean Y; Rain JD; Goguel A; Grange MJ; Vigneron N; Dupuy E; Mougeot-Martin M Ann Med Interne (Paris); 1998 Mar; 149(2):87-93. PubMed ID: 11490530 [TBL] [Abstract][Full Text] [Related]